Target intelligence / Profile preview

26S proteasome non-ATPase regulatory subunit 14 (PSMD14) (PSMD14)

Target
PSMD14
Molecular classification
Enzyme, Deubiquitinating enzyme, Metalloprotease, JAMM domain protein, Proteasome subunit
01

Overview

26S proteasome non-ATPase regulatory subunit 14 (PSMD14), also known as POH1 or Rpn11, is a critical zinc-dependent metalloprotease located within the 19S regulatory particle of the 26S proteasome (UniProt O00487). It belongs to the JAMM (JAB1/MPN/Mov34 metalloenzyme) family of deubiquitinating enzymes and is responsible for the essential step of removing polyubiquitin chains from substrates as they are translocated into the 20S catalytic core for degradation (PubMed: 29033320). By facilitating the recycling of ubiquitin and the unfolding of target proteins, PSMD14 maintains cellular protein homeostasis and prevents the accumulation of toxic protein aggregates (PubMed: 28190769). In many human cancers, including multiple myeloma and hepatocellular carcinoma, PSMD14 is frequently overexpressed, which promotes the degradation of tumor suppressors and helps malignant cells survive high levels of proteotoxic stress (PubMed: 28190769, PubMed: 28423570). Consequently, PSMD14 has emerged as a significant therapeutic target; small-molecule inhibitors like capzimin have been developed to block its metalloprotease activity, thereby inducing apoptosis in cancer cells by disrupting the proteasome-ubiquitin pathway (PubMed: 31104953). This approach provides a distinct mechanism of action compared to traditional 20S proteasome inhibitors like bortezomib, potentially overcoming resistance in clinical settings (PubMed: 31104953, PubMed: 28423570).

Other names
POH1Rpn1126S proteasome regulatory subunit RPN1126S proteasome non-ATPase subunit 1419S proteasome JAMM-domain deubiquitinase
02

Mechanism of action

Inhibition of the JAMM-domain metalloprotease activity to prevent substrate deubiquitination and subsequent proteasomal degradation.

03

Biological functions

DeubiquitinationProteasomal protein degradationCell cycle regulationDNA damage responseUbiquitin recyclingProtein homeostasis
04

Disease associations

CancerMultiple myelomaHepatocellular carcinomaColorectal cancerBreast cancerInflammation
05

Safety considerations

Off-target inhibition of other JAMM-domain metalloproteases (e.g., CSN5, AMSH)General proteotoxicity in non-malignant cellsNarrow therapeutic window
06

Interacting drugs

Capzimin

2 more in the full profile.

07

Biomarkers

PSMD14 protein expression levelsK48-linked polyubiquitin chain accumulationCHOP (C/EBP homologous protein) induction

Beyond the preview

Go deeper on 26S proteasome non-ATPase regulatory subunit 14 (PSMD14) (PSMD14).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 26S proteasome non-ATPase regulatory subunit 14 (PSMD14) (PSMD14).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call